• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

When do we treat hypercholesterolemia?

作者信息

Brown W V

机构信息

Department of Medicine, Emory University, Atlanta, Georgia 30322.

出版信息

Clin Cardiol. 1992 Nov;15(11 Suppl 3):III10-4; discussion III 15-7.

PMID:1477992
Abstract

Although the relationships between elevated total and low-density lipoprotein (LDL) cholesterol and coronary heart disease (CHD) are relatively well established and published treatment guidelines are available, clinicians face a number of complex issues when deciding whom to treat. Specific patient characteristics and potential risk factors, of which less is known, may influence treatment decisions. In this presentation, the current guidelines for treating patients with hypercholesterolemia are reviewed and therapeutic issues that must be considered when selecting patients for treatment are identified.

摘要

相似文献

1
When do we treat hypercholesterolemia?
Clin Cardiol. 1992 Nov;15(11 Suppl 3):III10-4; discussion III 15-7.
2
When do we treat hypercholesterolemia?我们何时治疗高胆固醇血症?
Clin Cardiol. 1992 Nov;15(11):III10-4; discussion III15-7.
3
Therapeutic intervention for hypercholesterolemia.
Clin Cardiol. 1992 Nov;15(11 Suppl 3):III18-21; discussion III22-4.
4
New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III.美国国家胆固醇教育计划成人治疗组第三次报告中的新治疗选择。
Am J Manag Care. 2002 Sep;8(12 Suppl):S301-7.
5
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.依折麦布/辛伐他汀调脂作用在性别、种族、年龄、基线低密度脂蛋白胆固醇水平及冠心病状态方面的一致性:汇总回顾性分析结果
Curr Med Res Opin. 2006 May;22(5):823-35. doi: 10.1185/030079906X100131.
6
High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.高密度脂蛋白胆固醇和甘油三酯作为预防和治疗冠状动脉疾病的治疗靶点。
Am Heart J. 2002 Dec;144(6 Suppl):S33-42. doi: 10.1067/mhj.2002.130301.
7
Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.以高密度脂蛋白胆固醇水平低为特征的人群中血脂异常的风险判定
Am Heart J. 2003 Dec;146(6):1052-9. doi: 10.1016/S0002-8703(03)00516-7.
8
Management of hypercholesterolaemia in the patient with diabetes.糖尿病患者高胆固醇血症的管理
Int J Clin Pract Suppl. 2002 Jul(130):27-32.
9
Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations.迎接新的美国国家胆固醇教育计划成人治疗组第三次报告(NCEP ATP III)指南的挑战:突破当前治疗局限。
Am J Manag Care. 2002 Feb;8(2 Suppl):S23-8; discussion S45-7.
10
HDL cholesterol: physiology, pathophysiology, and management.高密度脂蛋白胆固醇:生理学、病理生理学及管理
Curr Probl Cardiol. 2007 May;32(5):268-314. doi: 10.1016/j.cpcardiol.2007.01.004.